Merck’s Anti-Covid Pill Shows Better Effectiveness In Indian Study

Merck and Ridgeback Biotherapeutics’ Covid-19 antiviral pill molnupiravir reduced the risk of hospitalization by over 65% in a clinical trial conducted by their Indian partner Hetero, the company said Saturday, in what could be a boost for the treatment after poor results in earlier trials.